Clinical trial
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast…
NCT00193024 · SCRI Development Innovations, LLC, Other · Terminated
Key facts
| NCT number | NCT00193024 |
|---|---|
| Title | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer |
| Official title | A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Aventis Pharmaceuticals Industry Pharmacia and Upjohn |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Epirubicin |
| Enrollment | 90 |
| Start date | Sep 1, 2001 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2004 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: